Jia Huang1, Chongwu Li2, Hecheng Li3, Fanzhen Lv4, Long Jiang2, Hao Lin2, Peiji Lu2, Qingquan Luo2, Wenrong Xu1. 1. Jiangsu Key Laboratory of Medical Science and Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang xxxx, China. 2. Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai xxxx, China. 3. Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai xxxx, China. 4. Department of Thoracic Surgery, The Affiliated Huadong Hospital of Fudan University, Shanghai xxxx, China.
Abstract
BACKGROUND: Safety and short-term efficacy of robot-assisted thoracoscopic surgery (RATS) for early-stage non-small cell lung cancer (NSCLC) have been previously proven; however, RATS for N2 stage NSCLC was barely evaluated. The aim of this randomized controlled trial (RCT) was to explore the short-term outcome of RATS for cN2 stage NSCLC. METHODS: Total of 113 patients who were diagnosed with clinically single cN2 stage NSCLC were enrolled and randomly assigned to RATS and thoracotomy groups. The patients in RATS group were treated by lobectomy and mediastinal lymph node dissection using the da Vinci Surgical System, while the patients in thoracotomy group underwent lobectomy and mediastinal lymph node dissection from. And, short-term outcomes were analyzed statistically. RESULTS: The data from 108 subjects (58 in RATS and 55 in thoracotomy groups) were eligible for analyses. Five patients who received robot-assisted lobectomy initially was converted intraoperatively to open operation due to extensive pleural adhesion and equipment issues. And, one subject underwent robot-assisted surgery was died preoperatively due to pulmonary embolism. Compared with thoracotomy, RATS was associated with less intraoperative blood loss (86.3±41.1 vs. 165.7±46.4 mL, P<0.001), median chest duration (4 vs. 5, P<0.01), visual analog scores at postoperative day one to five (P<0.001), and slightly fewer incidence of postoperative complications. Also, both surgical approaches revealed comparable drainages and nodal harvest. The cancer residual margins occurred in one subject in RATS group and three patients in thoracotomy group (P=0.56). However, overall cost of subjects underwent RATS was higher than those received thoracotomy (100,367±19,251 vs. 82,002±20,434, P<0.001). CONCLUSIONS: Present study proves that the feasibility and safety of RATS lobectomy to treat patients with cN2 stage NSCLC, and it should be superior to thoracotomy due to lesser intraoperative blood loss. 2019 Translational Lung Cancer Research. All rights reserved.
BACKGROUND: Safety and short-term efficacy of robot-assisted thoracoscopic surgery (RATS) for early-stage non-small cell lung cancer (NSCLC) have been previously proven; however, RATS for N2 stage NSCLC was barely evaluated. The aim of this randomized controlled trial (RCT) was to explore the short-term outcome of RATS for cN2 stage NSCLC. METHODS: Total of 113 patients who were diagnosed with clinically single cN2 stage NSCLC were enrolled and randomly assigned to RATS and thoracotomy groups. The patients in RATS group were treated by lobectomy and mediastinal lymph node dissection using the da Vinci Surgical System, while the patients in thoracotomy group underwent lobectomy and mediastinal lymph node dissection from. And, short-term outcomes were analyzed statistically. RESULTS: The data from 108 subjects (58 in RATS and 55 in thoracotomy groups) were eligible for analyses. Five patients who received robot-assisted lobectomy initially was converted intraoperatively to open operation due to extensive pleural adhesion and equipment issues. And, one subject underwent robot-assisted surgery was died preoperatively due to pulmonary embolism. Compared with thoracotomy, RATS was associated with less intraoperative blood loss (86.3±41.1 vs. 165.7±46.4 mL, P<0.001), median chest duration (4 vs. 5, P<0.01), visual analog scores at postoperative day one to five (P<0.001), and slightly fewer incidence of postoperative complications. Also, both surgical approaches revealed comparable drainages and nodal harvest. The cancer residual margins occurred in one subject in RATS group and three patients in thoracotomy group (P=0.56). However, overall cost of subjects underwent RATS was higher than those received thoracotomy (100,367±19,251 vs. 82,002±20,434, P<0.001). CONCLUSIONS: Present study proves that the feasibility and safety of RATS lobectomy to treat patients with cN2 stage NSCLC, and it should be superior to thoracotomy due to lesser intraoperative blood loss. 2019 Translational Lung Cancer Research. All rights reserved.
Entities:
Keywords:
Da Vinci robot surgery system; N2; non-small cell lung cancer (NSCLC); thoracotomy
Authors: Giulia Veronesi; Domenico Galetta; Patrick Maisonneuve; Franca Melfi; Ralph Alexander Schmid; Alessandro Borri; Fernando Vannucci; Lorenzo Spaggiari Journal: J Thorac Cardiovasc Surg Date: 2009-12-28 Impact factor: 5.209
Authors: Scott J Swanson; James E Herndon; Thomas A D'Amico; Todd L Demmy; Robert J McKenna; Mark R Green; David J Sugarbaker Journal: J Clin Oncol Date: 2007-11-01 Impact factor: 44.544
Authors: Jia Huang; Yu Tian; Qian-Jun Zhou; Jun-Wei Ning; Ze-Nan Gu; Pei-Ji Lu; Jian-Tao Li; Hao Lin; Tian-Xiang Chen; Yun-Hai Yang; Min P Kim; Robert E Merritt; Marco Ghisalberti; Long Jiang; Qing-Quan Luo Journal: Transl Lung Cancer Res Date: 2021-12
Authors: Ji Hyeon Park; Samina Park; Chang Hyun Kang; Bub Se Na; So Young Bae; Kwon Joong Na; Hyun Joo Lee; In Kyu Park; Young Tae Kim Journal: J Chest Surg Date: 2022-02-05